Rhythm Pharmaceuticals to release results of trial testing setmelanotide for acquired hypothalamic obesity

From GlobeNewswire: 2025-04-06 12:00:00

Rhythm Pharmaceuticals will hold a conference call on April 7, 2025, to share topline results from the Phase 3 TRANSCEND trial evaluating setmelanotide in patients with acquired hypothalamic obesity. The trial included 120 patients and assessed the drug’s efficacy in reducing body mass index and improving quality of life. Acquired hypothalamic obesity is a rare form of obesity following brain damage, leading to rapid weight gain and insatiable hunger. Setmelanotide is currently approved to reduce excess body weight and maintain weight reduction in patients with specific genetic conditions related to obesity.



Read more at GlobeNewswire: Rhythm Pharmaceuticals to Announce Topline Results from